Day One Biopharmaceuticals (NASDAQ:DAWN) Price Target Lowered to $17.00 at Needham & Company LLC

Day One Biopharmaceuticals (NASDAQ:DAWN) had its price objective decreased by Needham & Company LLC from $18.00 to $17.00 in a research note issued to investors on Wednesday morning,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Several other research firms have also commented on DAWN. TD Cowen started coverage on Day One Biopharmaceuticals in a research report on Tuesday, January 13th. They issued a “buy” rating and a $34.00 price target for the company. Zacks Research upgraded Day One Biopharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 26th. Piper Sandler boosted their target price on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Day One Biopharmaceuticals in a report on Monday, December 29th. Finally, HC Wainwright cut their price objective on shares of Day One Biopharmaceuticals from $25.00 to $22.00 and set a “buy” rating on the stock in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $26.14.

Day One Biopharmaceuticals Stock Performance

Shares of DAWN opened at $10.93 on Wednesday. The company has a 50 day moving average price of $10.67 and a 200-day moving average price of $8.76. Day One Biopharmaceuticals has a fifty-two week low of $5.64 and a fifty-two week high of $13.20. The stock has a market capitalization of $1.12 billion, a PE ratio of -10.61 and a beta of -1.26.

Day One Biopharmaceuticals (NASDAQ:DAWN) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). The business had revenue of $53.72 million during the quarter, compared to the consensus estimate of $49.81 million. Day One Biopharmaceuticals had a negative return on equity of 23.14% and a negative net margin of 67.85%. Equities research analysts forecast that Day One Biopharmaceuticals will post -0.72 EPS for the current year.

Insiders Place Their Bets

In related news, insider Lauren Merendino sold 5,814 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total value of $67,442.40. Following the completion of the transaction, the insider directly owned 60,157 shares of the company’s stock, valued at $697,821.20. This trade represents a 8.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jeremy Bender sold 15,459 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total transaction of $179,324.40. Following the sale, the chief executive officer directly owned 204,603 shares in the company, valued at approximately $2,373,394.80. This represents a 7.02% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 36,461 shares of company stock valued at $422,948. 6.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Day One Biopharmaceuticals by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,989 shares of the company’s stock valued at $46,000 after buying an additional 1,029 shares during the last quarter. Federated Hermes Inc. acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth about $39,000. Quarry LP acquired a new stake in Day One Biopharmaceuticals during the 3rd quarter worth about $49,000. Ameritas Investment Partners Inc. grew its stake in Day One Biopharmaceuticals by 44.5% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,349 shares of the company’s stock valued at $48,000 after purchasing an additional 2,264 shares during the last quarter. Finally, CWM LLC increased its holdings in shares of Day One Biopharmaceuticals by 32.4% in the fourth quarter. CWM LLC now owns 8,373 shares of the company’s stock valued at $78,000 after purchasing an additional 2,051 shares during the period. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Day One Biopharmaceuticals

Here are the key news stories impacting Day One Biopharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and product momentum: Day One reported Q4 net product revenue that topped estimates and highlighted OJEMDA™ momentum and record revenue growth for 2025. Article Title
• Positive Sentiment: Company reaffirmed 2026 outlook and guidance: Day One reiterated 2026 U.S. net product revenue guidance of $225–$250M and disclosed the January acquisition of Mersana to expand its pipeline. Article Title
• Positive Sentiment: Analyst uplift from Wedbush: Wedbush raised its price target sharply to $30 and keeps an outperform rating, signaling at least one broker sees substantial upside vs. the current price. Article Title
• Neutral Sentiment: Other analysts trimmed targets but kept buy ratings: Needham cut its target to $17 and HC Wainwright trimmed to $22, yet both maintain positive ratings — a mixed signal on near-term valuation. Article Title
• Neutral Sentiment: Full earnings materials and transcripts available: The earnings slide deck and call transcript are posted for investors to review management commentary and guidance details. Article Title
• Neutral Sentiment: Short-interest data unclear: February short-interest reporting here shows effectively 0 shares (data appears inconsistent/NaN); no clear short-squeeze signal from the published short-interest figures.
• Negative Sentiment: EPS miss pressures sentiment: Reported EPS came in at ($0.21), missing the consensus of ($0.17); that earnings shortfall helps explain the stock selling off despite the revenue beat. Article Title

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.